以结构为导向的RNF43/ZNRF3化学定制的结体的开发,以实现膜蛋白向PROTAC的多功能设计

Jibin Cui1, Qingyun Zheng1, Yicheng Weng1

  • 1Institute of Translational Medicine, School of Pharmacy, School of Biomedical Engineering, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, Shanghai Jiao Tong University, Shanghai, 200240, China.

概括

研究人员为RNF43/ZNRF3 E3酶开发了新的结剂,使得膜蛋白的向降解成为可能. 这促进了蛋白质分解向仿真体 (PROTACs) 的发展,用于治疗具有挑战性的药物标,如PD-L1和EGFR.